Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes: The AMD annals initiative

Diabetes Care

Volumn 39, Issue 12, 2016, Pages 2278-2287

  Russo, Giuseppina T ^a   De Cosmo, Salvatore ^b   Viazzi, Francesca ^c   Pacilli, Antonio ^b   Ceriello, Antonio ^d,e   Genovese, Stefano ^e   Guida, Pietro ^f   Giorda, Carlo ^g   Cucinotta, Domenico ^a   Pontremoli, Roberto ^c   Fioretto, Paola ^h  

^a UNIVERSITY OF MESSINA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e IRCCS MULTIMEDICA   (Italy)

^f AMD Associazione Medici Diabetologi   (Italy)

^g Metabolism and Diabetes Unit   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ALBUMINURIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC DIET; DIABETIC NEPHROPATHY; DISEASE PREDISPOSITION; DYSLIPIDEMIA; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT; RETROSPECTIVE STUDY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; GLUCOSE BLOOD LEVEL; INCIDENCE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS;

AGED; ALBUMINURIA; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; FEMALE; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 85006093305     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1246     Document Type: Article

References (40)

1. Colhoun HM, Lee ET, Bennett PH, et al. Risk factors for renal failure: The WHO Mulitnational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl. 2):S46-S53
2. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55:1832-1839
3. Fioretto P, Dodson PM, Ziegler D, Rosenson RS. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol 2010;6:19-25
4. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH; American Diabetes Association. Diabetic nephropathy. Diabetes Care 2003;26(Suppl. 1):S94-S98
5. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982;2:1309-1311
6. Jandeleit-Dahm K, Cao Z, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int Suppl 1999;71:S31-S36
7. Wang Z, Jiang T, Li J, et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 2005;54:2328-2335
8. Sun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 2002;277:18919-18927
9. Abrass CK. Lipid metabolism and renal disease. Contrib Nephrol 2006;151:106-121
10. Gröne HJ, Hohbach J, Gröne EF. Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int Suppl 1996;54:S18-S22
11. Zager RA, Johnson A. Renal cortical cholesterol accumulation is an integral component of the systemic stress response. Kidney Int 2001; 60:2299-2310
12. Takemura T, Yoshioka K, Aya N, et al. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 1993;43:918-927
13. Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 1993; 22:72-82
14. Tsun JG, Yung S, Chau MK, Shiu SW, Chan TM, Tan KC. Cellular cholesterol transport proteins in diabetic nephropathy. PLoS One 2014;9: e105787
15. Morton J, Zoungas S, Li Q, et al.; ADVANCE Collaborative Group. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care 2012;35:2201-2206
16. Davis TM, Ting R, Best JD, et al.; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54:280-290
17. Hermans MP. Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. Diab Vasc Dis Res 2011;8:180-189
18. Tu ST, Chang SJ, Chen JF, et al. Prevention of diabetic nephropathy by tight target control in an asian population with type 2 diabetes mellitus: A 4-year prospective analysis. Arch Intern Med 2010;170:155-161
19. Xu J, Lee ET, Devereux RB, et al. A longitudinal study of risk factors for incident albuminuria in diabetic American Indians: The Strong Heart Study. Am J Kidney Dis 2008;51:415-424
20. Lin J, Hu FB, Mantzoros C, Curhan GC. Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes. Diabetologia 2010;53:263-267
21. Sacks FM, Hermans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: A global case-control study in 13 countries. Circulation 2014;129: 999-1008
22. Nicolucci A, Rossi MC, Arcangeli A, et al.; AMD-Annals Study Group. Four-year impact of a continuous quality improvement effort implemented by a network of diabetes outpatient clinics: The AMD-Annals initiative. Diabet Med 2010;27:1041-1048
23. De Cosmo S, Rossi MC, Pellegrini F, et al.; AMD-Annals Study Group. Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrol Dial Transplant 2014;29:657-662
24. De Cosmo S, Viazzi F, Pacilli A, et al.; AMDAnnals Study Group. Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi Annals initiative. Nephrol Dial Transplant 2015;30:1526-1533
25. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612
26. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232
27. Asztalos BF, Demissie S, Cupples LA, et al. LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial. Atherosclerosis 2006; 188:59-67
28. Russo GT, Horvath KV, Di Benedetto A, Giandalia A, Cucinotta D, Asztalos B. Influence of menopause and cholesteryl ester transfer protein (CETP) TaqIB polymorphism on lipid profile and HDL subpopulations distribution in women with and without type 2 diabetes. Atherosclerosis 2010;210:294-301
29. Russo GT, Giandalia A, Romeo EL, et al. Markers of systemic inflammation and Apo-AI containing HDL subpopulations in women with and without diabetes. Int J Endocrinol. 2014; 2014:607924
30. Russo GT, Giandalia A, Romeo EL, et al. Lipid and non-lipid cardiovascular risk factors in postmenopausal type 2 diabetic women with and without coronary heart disease. J Endocrinol Invest 2014;37:261-268
31. Zhou H, Tan KC, Shiu SW, Wong Y. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol Dial Transplant 2008;23:927-933
32. De Cosmo S, Menzaghi C, Prudente S, Trischitta V. Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence. Nephrol Dial Transplant 2013;28:29-36
33. Jauregui A, Mintz DH, Mundel P, Fornoni A. Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr Opin Nephrol Hypertens 2009;18:539-545
34. Salardi S, Balsamo C, Zucchini S, et al. High rate of regression from micro-macroalbuminuria to normoalbuminuria in children and adolescents with type 1 diabetes treated or not with enalapril: The influence of HDL cholesterol. Diabetes Care 2011;34:424-429
35. Jenkins AJ, Yu J, Alaupovic P, et al.; DCCT/EDIC Research Group. Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. J Diabetes Complications 2013;27:447-453
36. Mäkinen VP, Soininen P, Kangas AJ, et al.; Finnish Diabetic Nephropathy Study Group. Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: The FinnDiane Study. J InternMed 2013;273:383-395
37. Penno G, Solini A, Zoppini G, et al.; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Hypertriglyceridemia is independently associated with renal, but not retinal complications in subjects with type 2 diabetes: A cross-sectional analysis of the renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. PLoS One 2015;10:e0125512
38. Hanai K, Babazono T, Yoshida N, et al. Gender differences in the association between HDL cholesterol and the progression of diabetic kidney disease in type 2 diabetic patients. Nephrol Dial Transplant 2012;27:1070-1075
39. Stadler K, Goldberg IJ, Susztak K. The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease. Curr Diab Rep 2015;15:40
40. Han E, Yun Y, Kim G, et al. Effects of omega-3 fatty acid supplementation on diabetic nephropathy progression in patients with diabetes and hypertriglyceridemia. PLoS One 2016;11: e0154683